10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

COL9A1 Antibody (Center) Blocking Peptide

Synthetic peptide
Catalog # BP2762c

Specification

COL9A1 Antibody (Center) Blocking Peptide - Product Information

Primary Accession P20849

COL9A1 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 1297

Other Names
Collagen alpha-1(IX) chain, COL9A1

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP2762c was selected from the Center region of human COL9A1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

COL9A1 Antibody (Center) Blocking Peptide - Protein Information

Name COL9A1

Function
Structural component of hyaline cartilage and vitreous of the eye.

Cellular Location
Secreted, extracellular space, extracellular matrix

COL9A1 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

COL9A1 Antibody (Center) Blocking Peptide - Images

COL9A1 Antibody (Center) Blocking Peptide - Background

COL9A1 is one of the three alpha chains of type IX collagen, which is a minor (5-20%) collagen component of hyaline cartilage. Type IX collagen is usually found in tissues containing type II collagen, a fibrillar collagen. Studies in knockout mice have shown that synthesis of the alpha 1 chain is essential for assembly of type IX collagen molecules, a heterotrimeric molecule,and that lack of type IX collagen is associated with early onset osteoarthritis. Mutations in the COL9A1 gene are associated with osteoarthritis in humans, with multiple epiphyseal dysplasia, 6, a form of chondrodysplasia, and with Stickler syndrome, a disease characterized by ophthalmic, orofacial, articular, and auditory defects.

COL9A1 Antibody (Center) Blocking Peptide - References

Fresquet,M., J. Biol. Chem. 282 (48), 34634-34643 (2007)Liu,L.Y., Yi Chuan 29 (4), 427-432 (2007)Van Camp,G., Am. J. Hum. Genet. 79 (3), 449-457 (2006)Sivakumaran,T.A., J. Assoc. Res. Otolaryngol. 7 (2), 160-172 (2006)